Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

iCo Therapeutics Inc Updates On iDEAL Phase 2 Study For Treatment Of Diabetic Macular Edema


Tuesday, 18 Jun 2013 07:00am EDT 

iCo Therapeutics Inc announced that the iDEAL trial explores whether varying combinations and concentrations of iCo-007 are effective in improving visual acuity in people with DME-the cause of functional visual loss among working Americans, in which leakage of fluid from blood vessels in the eye causes the retina to swell, to blurred vision and blindness. The Phase 2 clinical trial is a multi-center study chaired by Quan Dong Nguyen, MD, MSc, Professor and Chair of Ophthalmology and Director of the Stanley M. Truhlsen Eye Institute at University of Nebraska Medical Center (UNMC) (previously Associate Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine). Recruitment took place at 27 clinical sites across the United States. In addition, the Retinal Imaging Research and Reading Center (RIRRC) based at the UNMC serves as the Reading Center for the iDEAL Study. The study follows patients for a 12 month period. During the trial, patients were randomized into one of the following four groups: Mono-therapy using repeated intravitreal dosing of iCo-007 at 350 µg; Mono-therapy using repeated intravitreal dosing of iCo-007 at 700 µg; Combination therapy using repeated intravitreal dosing of iCo-007 at 350 µg with laser photocoagulation and Combination therapy using repeated intravitreal dosing of iCo-007 at 350µg with ranibizumab (Lucentis) at 0.5 mg. 

Company Quote

0.07
0.0 +0.00%
29 Aug 2014